The sac evolution imaging follow-up after endovascular aortic repair: An international expert opinion-based Delphi consensus study

Giovanni Tinelli, MD, PhD,[a,b] Mario D'Oria, MD,[c] Simona Sica, MD,[a,b] Kevin Mani, MD, PhD,[d] Zoran Rancic, MD, PhD,[e] Timothy Andrew Resch, MD,[f] Flavia Beccia, MD,[g] Ali Azizzadeh, MD,[h] Marcelo Martins Da Volta Ferreira, MD,[i] Mauro Gargiulo, MD, PhD,[j] Sandro Lepidi, MD,[c] Yamume Tshomba, MD,[a,b] Gustavo S. Oderich, MD, FACS,[k] and Stéphan Haulon, MD, PhD,[l] SLIM F-U EVAR, Collaborative Study Group, *Rome, Trieste, Milano and Bologna, Italy; Uppsala and Zurich, Sweden; Copenhagen, Denmark; Birmingham, AL; Los Angeles, CA; Rio de Janeiro, Brazil; Houston, TX; and Paris, France*

ABSTRACT

Objective: Management of follow-up protocols after endovascular aortic repair (EVAR) varies significantly between centers and is not standardized according to sac regression. By designing an international expert-based Delphi consensus, the study aimed to create recommendations on follow-up after EVAR according to sac evolution.

Methods: Eight facilitators created appropriate statements regarding the study topic that were voted, using a 4-point Likert scale, by a selected panel of international experts using a three-round modified Delphi consensus process. Based on the experts' responses, only those statements reaching a grade A (full agreement ≥75%) or B (overall agreement ≥80% and full disagreement <5%) were included in the final document.

Results: One-hundred and seventy-four participants were included in the final analysis, and each voted the initial 29 statements related to the definition of sac regression (Q1-Q9), EVAR follow-up (Q10-Q14), and the assessment and role of sac regression during follow-up (Q15-Q29). At the end of the process, 2 statements (6.9%) were rejected, 9 statements (31%) received a grade B consensus strength, and 18 (62.1%) reached a grade A consensus strength. Of 27 final statements, 15 (55.6%) were classified as grade I, whereas 12 (44.4%) were classified as grade II. Experts agreed that sac regression should be considered an important indicator of EVAR success and always be assessed during follow-up after EVAR.

Conclusions: Based on the elevated strength and high consistency of this international expert-based Delphi consensus, most of the statements might guide the current clinical management of follow-up after EVAR according to the sac regression. Future studies are needed to clarify debated issues. (J Vasc Surg 2024;80:937-45.)

Keywords: Sac regression; Delphi consensus; EVAR; Follow-up; DUS; CTA

Endovascular aneurysm repair (EVAR) is the preferred choice of treatment for abdominal aortic aneurysm (AAA) in suitable patients, with reduced perioperative mortality compared with open repair.[1-3]

Current recommendations from the Society for Vascular Surgery for surveillance after EVAR include a computed tomography angiography (CTA) scan at 1 month and an annual duplex ultrasound (DUS) study if the initial CTA showed no endoleak.[4] According to the European Society for Vascular Surgery guidelines, all patients should be offered lifelong follow-up after EVAR, including a CTA scan at least every 5 years due to the risk of late failure and aneurysm progression. If necessary, more frequent imaging may be performed

with CTA or DUS based on the risk stratification of late complications after the first postoperative examination.[5,6]

Aneurysm sac shrinkage after EVAR has been proposed to indicate successful aneurysm exclusion and to be associated with significantly lower risk of mortality, reintervention rate, and improved outcomes.[7-11]

Nevertheless, follow-up protocols vary significantly between centers regarding both modality and frequency, and there are no surveillance protocols related to aneurysm sac shrinkage after EVAR.

Using an international expert-based Delphi consensus, this paper aims to investigate the practices endorsed at high-volume aortic centers and create recommendations on follow-up after EVAR according to sac evolution.

METHODS

Study design. A modified Delphi consensus process, following the methodology applied in prior literature, was used to obtain expert consensus on the role of sac regression during follow-up after EVAR.[12]

All surveys were submitted online and recorded through SurveyMonkey (https://www.surveymonkey.com). Invited experts were unaware of the identity of any other members of the international panel.

Institutional review board approval was not required due to the nature of the study (not involving patients data).

Core team and selection of the panel of international experts. The members of the core team were identified among the study principal investigators (G.T., M.D.O., S.S.). To ensure proper statistical analysis, a professional biostatistician with prior experience in Delphi-based research was also invited to join the core team (F.B.). Potential international experts to be included as panel members were selected among active physicians with specialization in vascular surgery or interventional radiology practicing in Europe, America, Asia, and Oceania. Physicians were identified based on prior publications in high-ranked vascular scientific journals and/or from international conferences' presentations on endovascular procedures, and/or among researchers serving on editorial boards for peer-reviewed journals relevant to the study practice. To be eligible for the expert panel, physicians were required to practice in a department that had performed more than 50 endovascular aortic cases yearly, and they had demonstrated competence as first operator with more than 50 EVAR procedures during their career.

Delphi methodology. A modified Delphi method was used to construct the expert consensus.[13] To develop the initial lists of statements for expert evaluation, a preliminary exploratory questionnaire (with multiple choice questions and option for open-ended suggestions) was administered to investigate the daily practice of follow-up after EVAR at each center or division. The answers provided by the questionnaire were analyzed by the core team, and the statements were designed accordingly. A compressed 4-point Likert-type scale was used to grade statements based on the level of agreement: agree (score 1), somewhat agree (score 2), somewhat disagree (score 3), and disagree (score 4). The central fifth grade of the Likert scale (eg, "no opinion") was omitted in view of the panel expertise and based on the assumption that invited experts would be able to offer their opinion for each statement. An open-ended question was used to guide changes to statements during the first two rounds. The statements were submitted to three rounds for evaluation and eventually modified by the core team to increase consensus according to the experts' open comments during the first two rounds. The first round was intended to submit the first formulation of the statements and collect a broad indication of the consensus strength. The second round was intended to obtain a detailed estimate of the consensus change from the original formulations to the modified formulations after they had been implemented as per the above process. The third round was intended to confirm the strength of consensus from the second to the third formulation.

Statistical analysis, evaluation of consensus strength, and consistency of scoring. Statistical analysis was performed with STATA 17.0 software (Stata Corporation).

The statements were tested in a three-round Delphi using a 4-point Likert scale. The proportion of experts rating a single item with a score of 1 "agree" or 2 "somewhat agree" compared with the total number of experts involved determined the content validity index, which ranged from 0% to 100%.

At consensus, the statements were evaluated according to the strength of agreement, and the consistency ranking, calculated from the previous round. The methodology is reported in Table I.

In addition to the agreement, the mean score and standard deviation, the significance of the change from the previous round according to Wilcoxon's test and Pearson's correlation, were evaluated. These items were used to confirm the strength of consensus. A P value of $<.25$ was considered a significant variation, considering that some degree of multiplicity was expected. Consistency was assessed by considering intraclass correlation coefficients and P values, Cohen's κ, and Fleiss' π, and test-rest reliability by the Bland-Altman plot.

The proportion of ratings exceeding the critical difference was estimated to monitor test-retest reliability according to Bland and Altman and was considered as a modifier of consistency: a proportion of outliers above 10% was considered indicative of significant

Table I. Strength and consistency grading definitions for statement submitted to the experts panel during the Delphi rounds

Grade	Rating	Definition
Strength grading		
A	Very strong	Full agreement ≥75%
B	Strong	Full agreement <75% Overall agreement ≥80% Full disagreement <5%
C	Fair	Full agreement <75% Overall agreement ≥80% Full disagreement ≥5%
D	Poor	Full disagreement ≥10%
Consistency grading		
I	Very high	Cohen's κ P value ≤.001 Intraclass correlation P value ≤.001
II	High	Cohen's κ and intraclass correlation coefficient P value ≤.001 in one and ≤.01 in the other analysis
III	Fair	Cohen's κ P value >.05 Fleiss's κ P value ≤.0001
IV	Poor	Cohen's κ P value >.05 Fleiss's κ P value >.01

heterogeneity among the experts and was used as a cut-off for downgrading consistency.

At the time of consensus, statements with strength grades A and B were considered of sufficient quality to be included in the final set of recommendations.

Criteria for selection or change of statement selection. The decision to refuse or modify and resubmit a statement was taken based on a composite of different statistical criteria. The predefined criteria for submission/resubmission after the first round were set as follows: statements with a proportion of full disagreement ≥10% and/or a mean score <2.0 were not resubmitted; all other statements were resubmitted after textual adaptations and/or statements merging, as appropriate. The predefined criteria for submission/resubmission after the second round were set as follows:

(1) statements with a proportion of overall agreement <80% and a proportion of full disagreement >5% (grades C and D) were removed from the consensus;
(2) statements with at least five among a proportion of "fully agree" >75% or a proportion of overall agreement >80%, a proportion of full disagreement <5%, a mean score change from the first to second round not statistically significant (Wilcoxon test—see above), a significant score correlation between the first and second round, a significant measure of agreement (Cohen's κ—see above), a significant intraclass correlation coefficient set for consistency, and a good test-retest reliability were to be accepted in their current form, unless suggestions from the core team recommended resubmission.

At the third and last round, only statements with grades of strength A and B were considered of sufficient quality to be included in the final set of recommendations.

RESULTS

Overview of participants and flow of Delphi exercise. Three-hundred and forty-three experts were initially contacted and invited to participate in the SLIM-FU study. One-hundred and seventy-four participants, all meeting the prespecified inclusion criteria, actively answered to all the three Delphi the survey rounds; 181 experts completed round 1, and 177 completed round 2.

The core team members designed 29 initial statements for the first round related to the definition of sac regression (Q1-Q9), EVAR follow-up (Q10-Q14), and the assessment and role of sac regression during follow-up (Q15-Q129). After round 1, a total of 18 statements were modified (Q3, Q6-Q10, Q12, Q14, Q16, Q19-Q21, and Q24-Q29); after round 2, two statements were rejected (Q9 and Q27).

Table II summarizes the proportion of consensus obtained by each statement at the third round. At the end of the process, 2 statements (6.9%) were rejected, 9 statements (31%) received a grade B consensus strength, and 18 statements (62.1%) reached a grade A consensus strength.

Table III summarizes the estimates of overall consistency across rounds estimated using Cohen's κ and Fleiss' π evaluation. Of 27 final statements, 15 statements (55.6%) were classified as grade I, whereas 12 (44.4%) were classified as grade II. No grade III-IV statements were reported.

Table II. Proportion of consensus obtained by each statement at the third round

Statement	Full agreement, %	Overall agreement, %	Full disagreement, %	Mean (SD)	Wilcoxon's test P value	Pearson correlation	Final grade
1	85.63	97.70	0.57	1.172 (0.461)	.212	<.0001	A
2	83.33	96.55	2.30	1.224 (0.58)	.880	<.0001	A
3	75.29	97.70	0.57	1.276 (0.52)	.048	1.000	A
4	85.06	97.13	0.57	1.184 (0.482)	.396	<.0001	A
5	90.23	98.85	0.57	1.115 (0.385)	.644	.3466	A
6	77.01	97.70	0.57	1.259 (0.512)	.241	.0247	A
7	71.84	98.28	0.57	1.305 (0.52)	.058	<.0001	B
8	79.31	97.13	0.57	1.241 (0.515)	.844	<.0001	A
10	75.86	91.38	2.87	1.356 (0.721)	.029	1.000	A
11	79.31	95.98	1.15	1.259 (0.566)	.201	<.0001	A
12	81.61	97.13	0	1.213 (0.476)	.465	<.0001	A
13	80.46	95.40	0.57	1.247 (0.55)	.738	.0007	A
14	78.16	94.25	1.15	1.287 (0.606)	.094	<.0001	A
15	95.40	99.43	0.57	1.057 (0.299)	.146	<.0001	A
16	87.93	98.28	0	1.138 (0.393)	.110	1.000	A
17	89.08	99.43	0	1.115 (0.337)	.393	<.0001	A
18	83.91	97.70	0	1.184 (0.444)	.687	<.0001	A
19	78.74	97.70	0	1.236 (0.477)	.012	.0011	A
20	74.71	93.68	2.87	1.345 (0.686)	.014	1.000	B
21	63.79	94.83	1.72	1.431 (0.648)	.839	<.0001	B
22	66.67	97.70	0.57	1.362 (0.549)	.858	<.0001	B
23	87.36	98.28	0.57	1.149 (0.431)	.460	<.0001	A
24	74.71	93.10	0.57	1.328 (0.619)	.402	<.0001	B
25	68.39	91.95	2.30	1.42 (0.707)	.402	.4080	B
26	68.97	91.38	2.30	1.42 (0.715)	.991	<.0001	B
28	74.71	96.55	1.72	1.305 (0.593)	.8490	<.0001	B
29	73.56	97.13	0.57	1.299 (0.54)	.587	<.0001	B

SD, Standard deviation.

The complete text of 27 statements that received a grade A or grade B consensus and, in the formulation, submitted to the final round are listed in Table IV.

Definition of sac regression and its prognostic relevance. The experts suggested (grade A) that sac regression should be defined as a reduction in the maximum diameter of the aneurysm sac by ≥5 mm (statement 1). According to the experts' opinion, aneurysm sac regression should be considered an important indicator of EVAR success (grade A), and different dedicated statements regarding its role (statements 3-8) were voted. Aneurysm sac regression is usually correlated with the absence of:

- endoleaks (I-III) that require secondary intervention after EVAR
- secondary intervention
- aneurysm rupture
- aneurysm-related mortality (grade A)

Grade B agreement was reached (statement 7) regarding the correlation with low rates of aneurysm-related complications after EVAR.

Follow-up after EVAR. The first follow-up after patient discharge following an elective EVAR should be a DUS or CTA within 3 months (grade A, consistency II). Experts identified different statements[11,12,14] with high strength (grade A) and consistency (I) regarding the follow-up: the imaging modality should be a DUS or a CTA (if DUS is not available or not diagnostic) at 1-, 2-, and 5-year follow-up.

Assessment and role of sac regression during follow-up. According to the experts' opinion, sac regression should always be assessed during follow-up after EVAR (statement 15—grade A). A DUS or a CTA should be used as first-line imaging modality to assess sac regression during follow-up (grade A, consistency II). However, the

Table III. Overall consistency across rounds estimated using Cohen's κ and Fleiss' π evaluation

Statement	Agreement, %	Cohen's κ		Fleiss π		Intraclass correlation		Test-retest	Overall consistency
		Coefficient	P value	Coefficient	P value	Coefficient (95% CI)	P value		
1	0.874	0.564	<.001	0.564	<.001	0.628 (0.529-0.71)	<.001	12.64	II
2	0.833	0.429	<.001	0.440	<.001	0.474 (0.351-0.582)	<.001	2.87	I
3	0.684	0.277	<.001	0.277	<.001	0.198 (0.051-0.336)	.004	5.17	I
4	0.828	0.398	<.001	0.402	<.001	0.493 (0.372-0.598)	<.001	9.20	I
5	0.862	0.277	.006	0.288	.004	0.292 (0.15-0.422)	<.001	13.79	II
6	0.782	0.346	<.001	0.346	<.001	0.323 (0.184-0.45)	<.001	9.20	I
7	0.770	0.386	<.001	0.380	<.001	0.453 (0.327-0.563)	<.001	8.62	I
8	0.805	0.432	<.001	0.434	<.001	0.453 (0.327-0.564)	<.001	3.45	I
10	0.626	0.196	.002	0.185	.004	0.224 (0.0782-0.36)	.001	8.05	II
11	0.782	0.426	<.001	0.421	<.001	0.635 (0.537-0.716)	<.001	7.47	I
12	0.776	0.322	<.001	0.317	<.001	0.491 (0.369-0.0595)	<.001	9.20	I
13	0.741	0.237	.002	0.238	.002	0.385 (0.251-0.504)	<.001	2.87	II
14	0.707	0.289	<.001	0.287	<.001	0.412 (0.281-0.528)	<.001	6.32	I
15	0.919	0.349	.003	0.367	.003	0.457 (0.332-0.567)	<.001	8.05	II
16	0.805	0.260	.003	0.263	.003	0.242 (0.098-0.377)	.001	2.87	II
17	0.851	0.320	.001	0.315	.001	0.411 (0.28-0.527)	<.001	14.94	II
18	0.828	0.350	<.001	0.355	<.001	0.461 (0.336-0.57)	<.001	17.24	II
19	0.741	0.381	<.001	0.385	<.001	0.347 (0.209-0.471)	<.001	3.45	I
20	0.661	0.291	<.001	0.281	<.001	0.237 (0.092-0.372)	.001	9.20	I
21	0.776	0.540	<.001	0.541	<.001	0.511 (0.393-0.613)	<.001	2.30	I
22	0.701	0.356	<.001	0.359	<.001	0.47 (0.346-0.578)	<.001	1.15	I
23	0.879	0.412	<.001	0.406	<.001	0.557 (0.445-0.651)	<.001	12.07	II
24	0.753	0.326	<.001	0.319	<.001	0.432 (0.303-0.545)	<.001	2.87	I
25	0.632	0.188	.002	0.186	.003	0.29 (0.149-0.42)	<.001	6.90	II
26	0.649	0.253	<.001	0.253	<.001	0.452 (0.325-0.562)	<.001	4.60	I
28	0.793	0.466	<.001	0.475	<.001	0.612 (0.51-0.697)	<.001	20.69	II
29	0.770	0.408	<.001	0.404	<.001	0.569 (0.46-0.661)	<.001	22.99	II

CI, Confidence interval.

comparison of two CTAs (baseline vs follow-up) is the most accurate imaging to detect sac regression after EVAR. In case of DUS imaging modality, sac regression should be measured in two projections at least; in case of CTA imaging modality, sac regression should be measured on the orthogonal axis using dedicated reconstruction software (statements 18 and 19—grade A).

The experts agree that sac regression can be usually expected to occur within 2 years after EVAR and that a diameter change within ±4.9 mm may be considered a clinically relevant parameter during follow-up (statements 21 and 22—grade B). However, a grade A agreement was reached (statement 23) regarding the clinically relevance of the sac increase (diameter change ≥5 mm).

In the case of sac regression, the follow-up protocol after EVAR should be continued (statement 24—grade B, consistency I). However, in case of EVAR within the instruction for use, sac regression is one of the parameters to consider for possible follow-up protocol changes (statement 26—grade B, consistency I).

Volumetric analysis and machine learning models may represent, in the future, an adjunctive tool to analyze AAA sac evolution during follow-up after EVAR (statements 28 and 29—grade B).

DISCUSSION

Endovascular treatment of abdominal aortic pathologies has evolved over the last two decades to the point of being the current first-line treatment modality for a large proportion of patients.[4,14] Owing to the inherent risk of endograft-related complications and secondary rupture that may occur during extended follow-up after EVAR, regular imaging surveillance is mandatory and dedicated recommendations have been formulated by vascular societies of Europe and North America.[4,5,15]

Table IV. Complete text of the 27 statements submitted to the final round

Statement number	Statement	Grade	Consistency
1	Sac regression definition Sac regression should be defined as a reduction in the maximum diameter of the aneurysm sac by ≥5 mm	A	II
2	Sac regression role Aneurysm sac regression should be considered an important indicator of EVAR success	A	I
3	Sac regression and endoleak Aneurysm sac regression is usually correlated with the absence of endoleaks that require secondary intervention after EVAR	A	I
4	Sac regression and endoleak Aneurysm sac regression is usually correlated with the absence of type I and III endoleaks after EVAR	A	I
5	Sac regression and aneurysm rupture Aneurysm sac regression is correlated with low rates of aneurysm rupture after EVAR	A	II
6	Sac regression and secondary intervention Aneurysm sac regression is usually correlated with low rates of secondary intervention after EVAR	A	I
7	Sac regression and aneurysm-related complications Aneurysm sac regression is usually correlated with low rates of aneurysm-related complications after EVAR	B	I
8	Sac regression and aneurysm-related mortality Aneurysm sac regression is usually correlated with reduced aneurysm-related mortality after EVAR	A	I
10	Follow-up The first follow-up after discharge of elective EVAR should be a DUS or CTA within 3 months	A	II
11	Follow-up At 1-year follow-up, the imaging modality should be a DUS or a CTA (if DUS is not available or not diagnostic)	A	I
12	Follow-up At 2-year follow-up, the imaging modality should be a DUS or a CTA (if DUS is not available or not diagnostic)	A	I
13	Follow-up At 3-year follow-up, the imaging modality should be a DUS or a CTA (if DUS is not available or not diagnostic)	A	II
14	Follow-up At 5-year follow-up, the imaging modality should be a DUS or a CTA (if DUS is not available or not diagnostic)	A	I
15	Sac regression assessment Sac regression should always be assessed during follow-up after EVAR	A	II
16	Sac regression assessment A DUS or a CTA should be used as first-line imaging modality to assess sac regression during follow-up	A	II
17	Sac regression assessment The comparison of two CTA (baseline vs follow-up) is the most accurate imaging to detect sac regression after EVAR	A	II
18	Sac regression assessment In case of DUS imaging modality, the sac regression should be measured in two projections at least (AP and LL)	A	II
19	Sac regression assessment In case of CTA imaging modality, the sac regression should be measured on the orthogonal axis using a dedicated reconstruction software	A	I
20	Sac regression assessment The baseline imaging used to assess sac regression after EVAR should be the preoperative CTA (performed within 6 months before EVAR) or the first postoperative DUS or CTA (performed within 3 months after EVAR)	B	I

Table IV. Continued.

Statement number	Statement	Grade	Consistency
21	Sac regression follow-up Sac regression can be usually expected to occur within 2 years after EVAR	B	I
22	Sac stable: role Sac stability (diameter change within ±4.9 mm) may be considered a clinically relevant parameter during follow-up after EVAR	B	I
23	Sac increase: role Sac increase (diameter change ≥5 mm) should be considered a clinically relevant parameter during follow-up after EVAR	A	II
24	Sac regression: role In case of sac regression, the follow-up protocol after EVAR should be continued	B	I
25	Sac regression: role In case of sac regression, the follow-up protocol after EVAR may be modified according to case-specific features (eg, on-IFU vs off-IFU, age of the patient, chronic anticoagulation, etc)	B	II
26	Sac regression: exception In case of EVAR within the IFU, sac regression is one of the parameters to consider for possible follow-up protocol changes	B	I
28	Follow-up: adjunctive tools Volumetric analysis may represent, in the future, an adjunctive tool to analyze AAA sac evolution during follow-up after EVAR	B	II
29	Follow-up: adjunctive tools Artificial intelligence and machine learning may represent, in the future, an adjunctive tool to analyze sac evolution during follow-up after EVAR	B	II

AAA, Abdominal aortic aneurysm; *AP*, antero-posterior; *CTA*, computed tomography angiography; *DUS*, duplex ultrasound; *EVAR*, endovascular aortic repair; *IFU*, instructions for use; *LL*, latero-lateral.

However, several unanswered questions remain, including the true benefits of prophylactic regular imaging follow-up after EVAR. Furthermore, despite clear guidelines, follow-up routines may vary significantly between centers, and some of this variability may be related to heterogeneity in the imaging metrics used to assess EVAR success.[16]

Our international expert-based Delphi exercise was able to achieve a remarkable consensus among a large group of EVAR experts regarding the importance of sac regression as a marker for EVAR success and clarify experts' opinions regarding its definitions, assessment, and natural history. Sac shrinkage during follow-up indicates successful exclusion of the aneurysm from arterial pressure and has been consistently shown to be a predictor of low risk of EVAR failure and overall mortality during postoperative follow-up.[9,17-19]

To the authors' knowledge, this is the first study to report a pragmatic approach to establish broad expert-based consensus on sac regression after EVAR. The majority of experts agreed on several key aspects including but not limited to the definition of sac regression as more than 5 mm as compared with baseline, the expectancy of sac regression to occur within the first 2 years after EVAR, the use of CTA as the optimal method to analyze sac regression, and the association of sac regression with the absence of clinically relevant endoleaks. It should be underlined that there is a broad consensus that the assessment of sac regression should be performed at each EVAR follow-up and that this assessment should be performed systematically both on CTA and DUS with a defined methodology that compared the diameter of the aneurysm at the time of measurement with previous measurements including the baseline evaluation close to the time of repair. Sac regression should be included in a broader evaluation of the patient-specific risk profile for EVAR failure that includes details of aortic anatomy and specific endograft characteristics. Further evidence from prospective trials is still needed to define more tailored follow-up protocols that could be safely and cost-effectively implemented by taking into consideration sac regression.

Our findings correlate well with available evidence surrounding the incidence and role of sac regression in patients with EVAR. A large observational study conducted in Japan documented cumulative rates of sac regression (>5 mm) at 1 year and 5 years in 50% and 62% of patients, respectively.[20] Similarly, a study from Ontario demonstrated a pattern of sac diameter change after EVAR, with the majority of sac regression occurring within the first 2 years.[21] Finally, other studies have identified that the early sac regression of greater than 5 mm within 1 to 2 years after implantation was associated with a significantly lower probability for delayed sac expansion, although a small proportion of patients would still go on to develop delayed sac expansion.[7,19-22] In fact, variability in sac regression can also be influenced by nonanatomic variables including age, sex, and original AAA

diameter, even after controlling for the presence or absence of an endoleak. Indeed, the ultimate biophysical relationship between specific endograft design and materials, and sac regression is yet to be determined.[21,23-25]

European Society for Vascular Surgery guidelines stratify patients after EVAR in low-, intermediate-, and high-risk groups based on the presence of endoleaks, adequate sealing and overlap zones, anatomy within instructions for use, and sac shrinkage.[5] In patients with adequate seal, no endoleak type I or III, but with the presence of endoleak type II, sac evolution determinates the patient's follow-up: if there is expansion ≥1 cm, the evaluation for reintervention is suggested; if the shrinkage is ≥1 cm instead of annual DUS, CTA at least every 5 years is suggested.

In the present study, experts agreed that CTA is the most accurate imaging modality to detect sac regression after EVAR. A metanalysis comparing DUS and CTA showed that the pooled sensitivity and specificity of DUS were 0.77 and 0.94, respectively.[26] Compared with CTA, it is reported that DUS has an overall lower sensitivity in the follow-up of patients after EVAR with 39% of positive predictive value.[27] However, DUS offers several potential advantages, including lower cost, no radiation exposure, shorter scan times, and the lack of any toxicity risk. Despite the widespread application of DUS worldwide, no recommendations have been published regarding the preferred method of maximum abdominal aortic diameter measurement that obtains the most reproducible aortic dimensions.[28]

In the current Delphi process, the participants agreed that during EVAR follow-up at 3 months, 1, 2, 3, and 5 years, imaging modality should be DUS or CTA if DUS is not available or not diagnostic. As the focus of the current consensus process was not to assess imaging frequency during follow-up, we cannot comment on the expert opinion on imaging frequency in patients with low risk for EVAR failure, including patients with significant sac shrinkage already early during follow-up. As agreed in the Delphi process, future development of artificial intelligence (AI)-based tools that may automate both evaluation of sac dynamics as well as the post-EVAR seal zone and endoleak evaluation may facilitate decision-making regarding EVAR follow-up algorithms.[29]

Interestingly, the expert panel did not rate the use of AI and machine learning as very strong and with very high consistency. AI could reduce human error in aneurysm sac measurement, is available 24/7, and could take into account all potential risk factors for aneurysm sac development: technical problems (with persistent or new endoleaks), aneurysm wall properties (potentially different biomechanical wall properties in patients with atherosclerosis and genetic aortopathies), and pure influences of pre- and postoperative thrombus volume after EVAR. Good-quality data for sac evolution analysis to create AI is also paramount, so it is possible that the algorithm will be biased by poor output data.[30-32] It could be that some panel experts do not believe that accurate data will ever be available and that the use of AI could ever be a comprehensive tool to analyze aneurysm sac evolution after EVAR.

Study limitations. This study must be interpreted within the context of its limitations. First, the Delphi methodology has accepted inherent shortcomings. Delphi studies have been criticized because the included items are chosen by the researchers, thereby potentially introducing bias. Second, because random selection was not feasible, because of the experts' inclusion criteria, a large preselected group of international experts proposed by the core team was invited, potentially introducing selection bias because they might not fully represent the real worldwide expertise, and results might also be partly influenced by local regulations and hospital policies. Third, the strength of consensus among experts is often considered to represent the same level of evidence as literature-based guidelines, although this might not necessarily hold true because guidelines, which are graded with a definition of strength recommendations, are based on literature analysis, whereas consensuses derived from the Delphi process can only be indicative of hints at good practice. Nonetheless, for clinical scenarios in which high-quality evidence may be difficult to obtain, the recommendations derived from a large body of experts may be seen as an important adjunct to support decision-making. To mitigate this limitation, whenever present, clinical practice guidelines from recognized scientific societies were consulted to ensure that the proposed statements would not be discordant.

AUTHOR CONTRIBUTIONS

DISCLOSURES

REFERENCES
1. Antoniou GA, Antoniou SA, Torella F. Editor's choice - endovascular vs. Open repair for abdominal aortic aneurysm: systematic review and meta-analysis of updated peri-operative and long term data of randomised controlled trials. *Eur J Vasc Endovasc Surg.* 2020;59: 385—397.

2. Mani K, Lees T, Beiles B, et al. Treatment of abdominal aortic aneurysm in nine countries 2005-2009: a vascunet report. *Eur J Vasc Endovasc Surg.* 2011;42:598–607.

3. Schermerhorn ML, Buck DB, O'Malley AJ, et al. Long-Term outcomes of abdominal aortic aneurysm in the medicare population. *N Engl J Med.* 2015;373:328–338.

4. Chaikof EL, Dalman RL, Eskandari MK, et al. The Society for Vascular Surgery practice guidelines on the care of patients with an abdominal aortic aneurysm. *J Vasc Surg.* 2018;67:2–77.

5. Wanhainen A, Van Herzeele I, Bastos Goncalves F, et al. Editor's choice – European society for vascular surgery (ESVS) 2024 clinical practice guidelines on the management of abdominal aorto-iliac artery aneurysms. *Eur J Vasc Endovasc Surg.* 2024;67:192–331.

6. Geraedts ACM, Mulay S, Vahl AC, et al. Editor's choice - post-operative surveillance and long term outcome after endovascular aortic aneurysm repair in patients with an initial post-operative computed tomography angiogram without abnormalities: the multicentre retrospective ODYSSEUS study. *Eur J Vasc Endovasc Surg.* 2022;63: 390–399.

7. Houbballah R, Majewski M, Becquemin JP. Significant sac retraction after endovascular aneurysm repair is a robust indicator of durable treatment success. *J Vasc Surg.* 2010;52:878–883.

8. Lee JT, Aziz IN, Lee JT, et al. Volume regression of abdominal aortic aneurysms and its relation to successful endoluminal exclusion. *J Vasc Surg.* 2003;38:1254–1263.

9. Bastos Gonçalves F, Baderkhan H, Verhagen HJ, et al. Early sac shrinkage predicts a low risk of late complications after endovascular aortic aneurysm repair. *Br J Surg.* 2014;101:802–810.

10. Antoniou GA, Alfahad A, Antoniou SA, Torella F. Prognostic significance of aneurysm sac shrinkage after endovascular aneurysm repair. *J Endovasc Ther.* 2020;27:857–868.

11. Ikeda S, Sato T, Kawai Y, et al. One-year sac regression is associated with freedom from fatal adverse events after endovascular aneurysm repair. *J Vasc Endovasc Surg.* 2023;77:136–142.e2.

12. D'Oria M, Bertoglio L, Bignamini AA, et al. Editor's Choice - PRINciples of optimal antithrombotiC therapy and coagulation managEment during elective fenestrated and branched EndovaScular aortic re-pairS (PRINCE^{2}SS): an International Expert Based Delphi Consensus Study. *Eur J Vasc Endovasc Surg.* 2022;63:838–850.

13. de la Fuente R, Fuentes R, Munoz-Gama J, Dagnino J, Sepúlveda M. Delphi method to achieve clinical consensus for a BPMN representation of the central venous access placement for training purposes. *Int J Environ Res Public Health.* 2020;17:3889.

14. Dua A, Desai SS, Seabrook GR, et al. The effect of Surgical Care Improvement Project measures on national trends on surgical site infections in open vascular procedures. *J Vasc Surg.* 2014;60: 1635–1639.

15. Schanzer A, Messina L. Two decades of endovascular abdominal aortic aneurysm repair: enormous progress with serious lessons learned. *J Am Heart Assoc.* 2012;1:e000075.

16. Karthikesalingam A, Page AA, Pettengell C, et al. Heterogeneity in surveillance after endovascular aneurysm repair in the UK. *Eur J Vasc Endovasc Surg.* 2011;42:585–590.

17. O'Donnell TFX, Deery SE, Boitano LT, et al. Aneurysm sac failure to regress after endovascular aneurysm repair is associated with lower long-term survival. *J Vasc Surg.* 2019;69:414–422.

18. Rastogi V, O'Donnell TFX, Marcaccio CL, et al. One-year aneurysm-sac dynamics are associated with reinterventions and rupture following infrarenal endovascular aneurysm repair. *J Vasc Surg.* 2024;79: 269–279.

19. Deery SE, Ergul EA, Schermerhorn ML, et al. Aneurysm sac expansion is independently associated with late mortality in patients treated with endovascular aneurysm repair. *J Vasc Surg.* 2018;67:157–164.

20. Fujimura N, Matsubara K, Takahara M, et al. Early sac shrinkage is a good surrogate marker of durable success after endovascular aneurysm repair in Japanese patients. *J Vasc Surg.* 2018;67:1410–1418. e1.

21. Jetty P, Husereau D, Kansal V, Zhang T, Nagpal S. Variability in aneurysm sac regression after endovascular aneurysm repair based on a comprehensive registry of patients in Eastern Ontario. *J Vasc Surg.* 2019;70:1469–1478.

22. Kirkham EN, Nicholls J, Wilson WRW, Cooper DG, Paravastu SCV, Kulkarni SR. Safety and validity of the proposed European society for vascular surgery infrarenal endovascular aneurysm repair surveillance protocol: a single centre evaluation. *Eur J Vasc Endovasc Surg.* 2021;62:879–885.

23. van der Laan MJ, Prinssen M, Bertges D, Makaroun MS, Blankensteijn JD. Does the type of endograft affect AAA volume change after endovascular aneurysm repair. *J Endovasc Ther.* 2003;10:406–410.

24. Väärämäki S, Uurto I, Suominen V. Possible implications of device-specific variability in post-endovascular aneurysm repair sac regression and endoleaks for surveillance categorization. *J Vasc Surg.* 2023;78:1204–1211.

25. Álvarez Marcos F, Llaneza Coto JM, Camblor Santervás LA, Zanabili Al-Sibbai AA, Alonso Pérez M. Five year post endovascular aneurysm repair aneurysmal sac evolution in the GREAT registry: an insight in diabetics using propensity matched controls. *Eur J Vasc Endovasc Surg.* Published online October 26, 2023. https://doi.org/10.1016/j.ejvs. 2023.10.033.

26. Mirza TA, Karthikesalingam A, Jackson D, et al. Duplex ultrasound and contrast-enhanced ultrasound versus computed tomography for the detection of endoleak after EVAR: systematic review and bivariate meta-analysis. *Eur J Vasc Endovasc Surg.* 2010;39:418–428.

27. Jean-Baptiste E, Feugier P, Cruzel C, et al. Computed tomography-aortography versus color-duplex ultrasound for surveillance of endovascular abdominal aortic aneurysm repair: a prospective multicenter diagnostic-accuracy study (the ESSEA trial). *Circ Cardiovasc Imaging.* 2020;13:e009886.

28. Bissacco D, Mandigers TJ, Savaré L, et al. Editor's Choice - Comparison of the Reproducibility of Ultrasound Calliper Placement Methods in Abdominal aortic diameter measurements: a systematic review and meta-analysis of diagnostic test accuracy studies. *Eur J Vasc Endovasc Surg.* 2023;66:620–631.

29. Adam C, Fabre D, Mougin J, et al. Pre-surgical and post-surgical aortic aneurysm maximum diameter measurement: full automation by artificial intelligence. *Eur J Vasc Endovasc Surg.* 2021;62: 869–877.

30. Kiessling J, Brunnberg A, Holte G, Eldrup N, Sörelius K. Artificial intelligence outperforms Kaplan-meier analyses estimating survival after elective treatment of abdominal aortic aneurysms. *Eur J Vasc Endovasc Surg.* 2023;65:600–607.

31. Caradu C, Pouncey AL, Lakhlifi E, Brunet C, Bérard X, Ducasse E. Fully automatic volume segmentation using deep learning approaches to assess aneurysmal sac evolution after infrarenal endovascular aortic repair. *J Vasc Surg.* 2022;76:620–630.e3.

32. Raffort J, Adam C, Carrier M, et al. Artificial intelligence in abdominal aortic aneurysm. *J Vasc Surg.* 2020;72:321–333.e1.